Related Experiment Video
Updated: Jun 15, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Periprocedural hemoglobin drop and contrast-induced nephropathy in percutaneous coronary intervention patients
Kang Hyu Lee1, Sang Rok Lee, Kyung Pyo Kang
1Division of Cardiology, Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Korea.
Insights
A drop in hemoglobin greater than 1 g/dL during periprocedural care is a significant predictor of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI). This finding aids in identifying patients at higher risk for CIN.
Area of Science:
- Cardiology
- Nephrology
- Interventional Radiology
Background:
- Contrast-induced nephropathy (CIN) increases mortality and cardiovascular risks post-percutaneous coronary intervention (PCI).
- The association between CIN and hemoglobin levels has been debated.
- Identifying novel risk factors for CIN is crucial for patient management.
Purpose of the Study:
- To assess the clinical utility of periprocedural hemoglobin drop as a risk factor for CIN.
- To investigate the relationship between hemoglobin changes and CIN development after PCI.
Main Methods:
- A cohort of 537 patients undergoing PCI was studied.
- Patients were categorized into two groups: those who developed CIN (n=51) and those who did not (n=486).
- Iodixanol was used as the contrast agent; CIN was defined by a specific rise in serum creatinine within 48 hours.
Main Results:
- No significant differences in baseline cardiovascular risk factors were observed between groups, except for anthropometric measures and baseline hemoglobin.
- Patients who developed CIN had lower pre-PCI and post-PCI hemoglobin levels.
- A periprocedural hemoglobin drop exceeding 1 g/dL was identified as an independent predictor of CIN via logistic regression analysis.
Conclusions:
- A periprocedural hemoglobin drop of >1 g/dL is a significant independent predictor of CIN.
- This finding holds true even when using less nephrotoxic contrast agents like iodixanol.
- Hemoglobin drop serves as an important, previously underappreciated, risk factor for CIN in PCI patients.
Background And Objectives:
The development of contrast-induced nephropathy (CIN) is associated with an increased risk of death and late cardiovascular events after percutaneous coronary intervention (PCI). The relationship between CIN and hemoglobin drop has been controversial. The aim of this study was to evaluate the clinical usefulness of periprocedural hemoglobin drop as a nontraditional risk factor for CIN.
Subjects And Methods:
Five-hundred thirty-seven patients who underwent PCI were divided into 2 groups: Group I (486 patients: patients who did not develop CIN) and Group II (51 patients: patients who developed CIN). All patients were administered iodixanol as contrast media during coronary angiography. CIN is defined as a rise in serum creatinine of >/=25% or >/=0.5 mg/dL above the baseline value within 48 hours after contrast administration.
Results:
BASELINE CLINICAL AND CARDIOVASCULAR RISK FACTORS WERE NOT SIGNIFICANTLY DIFFERENT BETWEEN THE TWO GROUPS, EXCEPT FOR LOW ABDOMINAL CIRCUMFERENCE (GROUP I : Group II=87.9+/-9.0 cm : 81.2+/-15.1 cm, p=0.024), body weight (Group I : Group II=63.5+/-10.6 kg : 59.7+/-9.2 kg, p=0.008), body mass index (BMI) (Group I : Group II=24.4+/-3.4 kg/m(2) : 23.4+/-2.8 kg/m(2), p=0.032), pre-PCI hemoglobin (Group I : Group II=13.2+/-2.0 g/dL : 12.3+/-2.0 g/dL, p=0.003), and post-PCI hemoglobin (Group I : Group II=12.4+/-1.9 g/dL : 11.5+/-1.8 g/dL, p=0.001). Multiple logistic regression analysis showed that a periprocedural drop in hemoglobin (>1 g/dL) was an independent predictor of CIN, like other known risk factors.
Conclusion:
A periprocedural drop in hemoglobin of more than 1 g/dL is another important independent predictor for CIN, even in patients administered the lowest nephrotoxic contrast agent, iodixanol, during PCI.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management
Imaging Studies VII: Vascular Imaging
Hemodialysis II: Procedure and Complications
Cardiac Catheterization II: Right Heart Catheterization
Imaging Studies for Cardiovascular System V: CT
